<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJCB</journal-id><journal-title-group><journal-title>Hans Journal of Computational Biology</journal-title></journal-title-group><issn pub-type="epub">2164-5426</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJCB.2020.101001</article-id><article-id pub-id-type="publisher-id">HJCB-34115</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJCB20200100000_10631722.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>生命科学</subject></subj-group></article-categories><title-group><article-title>
 
 
  基于mRNA表达谱比较胃癌和房颤的分子生物特征
  Comparing the Molecular Biological Characteristics between Gastric Cancer and Atrial Fibrillation Based on mRNA Expression Profiles
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>曾</surname><given-names>伟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>董</surname><given-names>昌龙</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>高</surname><given-names>枫林</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>光斌</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>曾</surname><given-names>红娟</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>饶</surname><given-names>妮妮</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>电子科技大学生命科学与技术学院，四川 成都； 四川轻化工大学自动化与信息工程学院，四川 自贡</addr-line></aff><aff id="aff4"><addr-line>电子科技大学生命科学与技术学院，四川 成都；电子科技大学广东电子信息工程研究院，广东 东莞</addr-line></aff><aff id="aff3"><addr-line>电子科技大学生命科学与技术学院，四川 成都</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>06</day><month>02</month><year>2020</year></pub-date><volume>10</volume><issue>01</issue><fpage>1</fpage><lpage>14</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  有研究显示，新发房颤患者的癌症风险显著增加，新发癌症患者的房颤风险也有所增加，说明两种疾病之间可能存在一定的联系。传统上，有关癌症和房颤的机制研究大多是独立开展的。本研究以胃癌为例，基于mRNA表达谱，采用生物信息学工具比较分析胃癌与房颤在分子水平上的生物特征，为癌症与房颤共病的机制研究提供一定的理论基础。首先从mRNA表达谱中分别筛选胃癌与房颤相关的差异表达mRNAs，再采用差异表达mRNAs分别富集胃癌与房颤的生物特征；然后通过分别构建胃癌与房颤的蛋白质–蛋白质相互作用网络，识别胃癌与房颤相关的重要靶向分子；最后，比较与分析胃癌与房颤在分子水平上的联系。研究结果表明，胃癌与房颤有一些相同的分子生物特征，二者相关的重要靶向分子也存在一定联系。
   Some researches have shown that there was a significant increase in cancer risk in patients with new onset atrial fibrillation (AF), and there is also an increased risk of AF in new cancer patients. It suggests that there may be a relationship between the two diseases. Traditionally, the study on mechanisms of cancer and atrial fibrillation has been conducted independently. Based on mRNA expression profiles and by using bioinformatics tools, this study selected gastric cancer (GC) and AF as the objects of study, compared and analyzed the biological characteristics of GC and AF at the molecular level so as to provide a theoretical basis for the study on the mechanism of comorbidity between cancer and AF. Firstly, differentially expressed mRNAs associated with GC and AF were screened from mRNA expression profiles respectively, and then biological characteristics of GC and AF were enriched using differentially expressed mRNAs. Secondly, some key targeting mole cules related to GC and AF were identified from protein-protein interaction networks of them, re spectively. Finally, we compared and analyzed the relationships at the molecular level between GC and AF. The results showed that GC and AF have some of the same molecular biological characte ristics. There is also a certain relationship between the two key targeting molecules.
  
 
</p></abstract><kwd-group><kwd>mRNA表达谱，胃癌，房颤，分子生物特征，靶向分子, mRNA Expression Profiles</kwd><kwd> Gastric Cancer</kwd><kwd> Atrial Fibrillation</kwd><kwd> Molecular Biological Characteristics</kwd><kwd> Targeting Molecules</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>基于mRNA表达谱比较胃癌和房颤的分子生物特征<sup> </sup></title><p>曾伟<sup>1,2</sup>，董昌龙<sup>1</sup>，高枫林<sup>1</sup>，王光斌<sup>1</sup>，曾红娟<sup>1</sup>，饶妮妮<sup>1,3*</sup></p><p><sup>1</sup>电子科技大学生命科学与技术学院，四川 成都</p><p><sup>2</sup>四川轻化工大学自动化与信息工程学院，四川 自贡</p><p><sup>3</sup>电子科技大学广东电子信息工程研究院，广东 东莞</p><disp-formula id="hanspub.34115-formula8"><graphic xlink:href="//html.hanspub.org/file/1-1690087x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2020年1月10日；录用日期：2020年1月31日；发布日期：2020年2月6日</p><disp-formula id="hanspub.34115-formula9"><graphic xlink:href="//html.hanspub.org/file/1-1690087x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>有研究显示，新发房颤患者的癌症风险显著增加，新发癌症患者的房颤风险也有所增加，说明两种疾病之间可能存在一定的联系。传统上，有关癌症和房颤的机制研究大多是独立开展的。本研究以胃癌为例，基于mRNA表达谱，采用生物信息学工具比较分析胃癌与房颤在分子水平上的生物特征，为癌症与房颤共病的机制研究提供一定的理论基础。首先从mRNA表达谱中分别筛选胃癌与房颤相关的差异表达mRNAs，再采用差异表达mRNAs分别富集胃癌与房颤的生物特征；然后通过分别构建胃癌与房颤的蛋白质–蛋白质相互作用网络，识别胃癌与房颤相关的重要靶向分子；最后，比较与分析胃癌与房颤在分子水平上的联系。研究结果表明，胃癌与房颤有一些相同的分子生物特征，二者相关的重要靶向分子也存在一定联系。</p><p>关键词 :mRNA表达谱，胃癌，房颤，分子生物特征，靶向分子</p><disp-formula id="hanspub.34115-formula10"><graphic xlink:href="//html.hanspub.org/file/1-1690087x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-1690087x8_hanspub.png" /> <img src="//html.hanspub.org/file/1-1690087x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>癌症泛指各种类型的恶性肿瘤。目前所知，癌症主要与生活环境、饮食习惯、遗传与免疫因素等有关 [<xref ref-type="bibr" rid="hanspub.34115-ref1">1</xref>]。房颤是严重的心房电活动紊乱，是常见的心律失常之一。房颤与脑卒中和心力衰竭等密切相关 [<xref ref-type="bibr" rid="hanspub.34115-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.34115-ref3">3</xref>]。高血压和瓣膜性心脏病是造成房颤的两个最常见危险因子，而心脏衰竭、冠状动脉疾病、心肌症和先天性心脏病等与心脏相关的疾病也会增加患房颤的机率 [<xref ref-type="bibr" rid="hanspub.34115-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.34115-ref5">5</xref>]。</p><p>有研究表明，房颤患者的癌症发生率明显高于一般人群，尤其是胃、肾和脑等部位的癌症 [<xref ref-type="bibr" rid="hanspub.34115-ref6">6</xref>]。新发房颤(new onset atrial fibrillation)定义为在一年内至少两次门诊诊断为新房颤或住院期间至少一次的新房颤诊断，并将房颤发病的索引日期定义为首次诊断房颤的日期 [<xref ref-type="bibr" rid="hanspub.34115-ref7">7</xref>]。术后新发心房颤动是心脏手术后最常见的并发症 [<xref ref-type="bibr" rid="hanspub.34115-ref8">8</xref>]。与一般人群相比，新发房颤患者患癌症的风险更高。这种关联在男性和女性以及所有年龄组中都很显著 [<xref ref-type="bibr" rid="hanspub.34115-ref7">7</xref>]。癌症患者患房颤的风险也会增加，尤其是在确诊后的90天内 [<xref ref-type="bibr" rid="hanspub.34115-ref9">9</xref>]。这表明癌症和房颤可能存在一定的联系。</p><p>早在20世纪40年代和50年代就有关于易患房颤的癌症报道，主要涉及肿瘤心脏浸润、心脏机械压力和肿瘤胸外科手术等 [<xref ref-type="bibr" rid="hanspub.34115-ref9">9</xref>]。即使是接受药物治疗的非手术性癌症，患者也表现出更高的房颤频率。这可能是由辐射、化疗药物和癌症靶向治疗引起的。虽然手术和包括化疗在内的其他药物治疗可能是导致房颤的因素，但即使没有任何癌症特异性治疗，癌症患者房颤的发生率仍在增加 [<xref ref-type="bibr" rid="hanspub.34115-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.34115-ref11">11</xref>]。癌症中房颤的发生可能与共病状态或直接的肿瘤效应有关，也可能是癌症手术或医学治疗的并发症，而炎症可能是这两种情况的共同特征 [<xref ref-type="bibr" rid="hanspub.34115-ref12">12</xref>]。癌症导致全身性炎症，通过心房重构促进房颤 [<xref ref-type="bibr" rid="hanspub.34115-ref10">10</xref>]。癌症治疗过程中房颤的发展是一个不良预后因素，影响恶性疾病的预后，并对治疗策略和治疗结果会产生影响 [<xref ref-type="bibr" rid="hanspub.34115-ref13">13</xref>]。然而，癌症与房颤之间相互影响的机制尚不清楚。</p><p>单独针对各种癌症和房颤的病理生理机制已开展了大量研究。胃癌是发生在胃部黏膜的癌症，它不仅与癌症普遍的危险因子有关，还与慢性胃病等有关 [<xref ref-type="bibr" rid="hanspub.34115-ref14">14</xref>]。迄今为止，还没有文献报道胃癌与房颤在分子水平上的联系。因此，本文拟通过分析胃癌和房颤患者的mRNA表达谱，分别筛选两种疾病相关的差异表达mRNAs并富集疾病相关的生物功能；通过预测两种疾病差异表达mRNAs对应的蛋白质–蛋白质相互作用关系，分别识别两种疾病相关的潜在重要靶向分子；通过比较两种疾病相关的分子生物特征和潜在重要靶向分子，发现胃癌和房颤之间的联系，为理解两种疾病的共病机制提供一定的理论基础。</p></sec><sec id="s4"><title>2. 材料和方法</title><sec id="s4_1"><title>2.1. 微阵列数据</title><p>本文采用的mRNA表达谱数据从GEO数据库下载(https://www.ncbi.nlm.nih.gov/geo/)。胃癌mRNA表达谱的进入号(Access number)是GSE54129。该表达数据包含111个胃癌患者样本和21个正常人样本。房颤mRNA表达谱的进入号是GSE79768。该表达数据包含14个样本持续性房颤和12个窦性心律样本。</p></sec><sec id="s4_2"><title>2.2. 方法</title><p>本文方法的架构如图1所示。首先从GEO数据库分别下载胃癌和房颤的mRNA表达数据；然后采用T检验和倍数法从case-control型的mRNA表达数据中筛选差异表达的mRNAs，并用差异表达mRNAs做GO (Gene ontology, GO)和KEGG (Kyoto Encyclopedia of Genes and Genomes, KEGG)通路富集分析；接着采用STRING工具分别预测两种疾病差异表达mRNAs对应的蛋白质–蛋白质相互作用(Protein-protein interaction, PPI)关系，并构建PPI网络，通过分析PPI网络特征，分析挖掘胃癌和房颤潜在的重要靶向</p><p>图1. 本文方法构架图</p><p>分子。最后比较两种疾病在重要靶向分子、生物功能和通路等分子生物特征上的异同。</p><sec id="s4_2_1"><title>2.2.1. 筛选差异表达mRNAs</title><p>采用T检验和倍数法分别根据胃癌和房颤mRNA表达谱筛选疾病相关的显著差异表达mRNAs，显著性差异条件设置为P &lt; 0.05和Fold change &gt; 2，再采用多次测试对P值进行校正。</p></sec><sec id="s4_2_2"><title>2.2.2. 用差异表达mRNAs做富集分析</title><p>应用DAVID分析工具(https://david.ncifcrf.gov/)分别对胃癌和房颤相关的差异表达mRNAs做GO富集分析和KEGG富集分析。通过GO分析理解两种疾病的生物过程(biological process)、细胞组分(cellular component)和分子功能(molecular function)。通过KEGG分析分别发现与两种疾病相关的生物通路。</p></sec><sec id="s4_2_3"><title>2.2.3. 构建PPI网络与筛选靶向分子</title><p>分别根据胃癌和房颤的差异表达mRNAs，利用STRING数据库(Version: 11.0) (https://string-db.org/)去预测差异表达mRNAs对应的PPI关系对 [<xref ref-type="bibr" rid="hanspub.34115-ref15">15</xref>]。Organism选择“Homo sapiens”。PPI关系对的推断来源设置包含了数据库的数据、实验、文本挖掘、基因组共现、基因组邻域、实验共表达和基因融合。最低关系分数(minimum required interaction score)设置为最高可信度0.900。</p><p>我们根据PPI网络中节点的度、中介中心性和紧密中心性来筛选重要的节点，并把对应的蛋白质分子作为疾病相关的潜在重要靶向分子。节点的度(Degree)是指和该节点相关联的边的条数。一个生物网络中节点度值越大，那么该节点在网络中的重要性更大 [<xref ref-type="bibr" rid="hanspub.34115-ref16">16</xref>]。中介中心性(Betweenness Centrality)是一个节点在两个其他节点之间最短路径上的次数。在蛋白质–蛋白质相互作用网络中，如果药物靶点是起重要中介作用的蛋白质，则其中介中心性可能高于其他靶点 [<xref ref-type="bibr" rid="hanspub.34115-ref17">17</xref>]。紧密中心性(Closeness Centrality)是一种全局中心性度量，用于确定节点在网络中小世界行为的关键程度。紧密中心性越大说明这个节点到其他所有节点的距离越近 [<xref ref-type="bibr" rid="hanspub.34115-ref18">18</xref>]。</p></sec><sec id="s4_2_4"><title>2.2.4. 比较与分析胃癌和房颤的分子生物特征</title><p>通过比较胃癌和房颤相关的GO和KEGG富集分析结果，探究两种疾病在生物过程、细胞组成和分子功能以及生物通路等生物特征方面是否有相同之处。通过比较胃癌和房颤相关的重要靶向分子，探究两种疾病之间是否有相同的靶向分子以及这些靶向分子在两种疾病中的作用。</p></sec></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 差异表达的mRNAs</title><p>在筛选胃癌和房颤相关的差异表达mRNAs时，阈值条件均设置为P &lt; 0.05，Fold change &gt; 2和PFDR &lt; 0.05。我们筛选到2066个胃癌相关的差异表达mRNAs (其中，927个上调，1139个下调)；筛选到38个房颤相关的差异表达mRNAs (其中，23个上调，15个下调)。</p></sec><sec id="s5_2"><title>3.2. 富集分析结果</title><sec id="s5_2_1"><title>3.2.1. 被富集的分子生物特征</title><p>在GO数据库中，采用胃癌相关的差异表达mRNAs富集到353个显著的生物过程条目、58个显著的细胞组分条目和87个显著的分子功能条目，最显著的前10项如图2(a)~(c)所示。其中，(a)：生物过程(biological process, BP)，(b)：细胞组分(cellular component, CC)，(c)：分子功能(molecular function, MF)。图2(a)~(c)表明，胃癌的生物过程主要集中在炎症反应(inflammatory response)、细胞外基质的组成(extracellular matrix organization)和细胞粘附(cell adhesion)等方面；细胞组分主要集中在细胞外基质(extracellular matrix)、胶原蛋白三聚物(collagen trimer)和内质网腔(endoplasmic reticulum lumen)等方面；分子功能主要集中在肝素</p><p>图2. 用差异表达mRNAs富集的最显著GO条目。(a)~(c)是最显著的胃癌相关GO条目；(a)：生物进程；(b)：细胞组分；(c)：分子功能；(d)~(f)是最显著的房颤相关GO条目；(d)：生物进程；(e)：细胞组分；(f)：分子功能。柱状图旁边的数字代表富集到该条目的差异表达mRNAs的数量</p><p>结合(heparin binding)、趋化因子的活性(chemokine activity)和细胞外基质结合(extracellular matrix binding)等方面。</p><p>采用房颤相关的差异表达mRNAs富集到15个显著的生物过程条目、4个显著的细胞组分条目和1个显著的分子功能条目，最显著的前10项如图2(d)~(f)所示(注：细胞组分和分子功能显著的条目不足10项)。其中，(d)：生物过程，(e)：细胞组分，(f)：分子功能。图2(d)~(f)表明，房颤的生物过程主要集中在粘膜固有免疫反应(innate immune response in mucosa)、趋化性(chemotaxis)和上皮细胞分化(epithelial cell differentiation)等方面；细胞组分主要集中在嗜苯胺蓝的颗粒内腔(azurophil granule lumen)、细胞外的外泌体(extracellular exosome)和细胞外隙(extracellular space)等方面；分子功能只富集到凹槽的结合(notch binding)。</p></sec><sec id="s5_2_2"><title>3.2.2. 被富集的生物通路</title><p>在KEGG数据库中，采用胃癌相关的差异表达mRNAs富集到57个显著的生物通路，其中最显著的10条生物通路如图3所示。它们主要集中在化学致癌(Chemical carcinogenesis)、细胞色素P450的药物代谢(Drug metabolism-cytochrome P450)和视黄醇的新陈代谢(Retinol metabolism)等方面。</p><p>图3. 胃癌相关的差异表达mRNAs富集的重要通路。柱状图旁边的数字代表富集到该条目的差异表达mRNAs的数量</p><p>采用房颤相关的差异表达mRNAs没有富集到显著的生物通路。</p></sec></sec><sec id="s5_3"><title>3.3. 基于PPI网络筛选的胃癌和房颤相关重要靶向分子</title><p>在STRING数据库中，分别采用胃癌和房颤的差异表达mRNAs预测各自的PPI关系对。构建的胃癌PPI网络包含24,500条PPI关系对(边)和4772个蛋白质(节点)；构建的房颤PPI网络包含631条PPI关系对(边)和182个蛋白质(节点)。利用cytoscape软件将胃癌和房颤的PPI网络可视化，并对网络的特征进行分析。</p><p>我们首先计算胃癌和房颤PPI网络的节点度、中介中心性和紧密中心性等网络特征，然后根据节点的度值排序网络中的所有蛋白质。具有相同度值的蛋白质再根据它们的中介中心性数值排序，具有相同中介中心性的蛋白质，则根据它们的紧密中心性排序。按照以上排序规则，胃癌和房颤PPI网络中所有蛋白质进行排序。排序前茅的那些蛋白质，其在网络中的重要性更大，作为药物靶点中介作用更大，与其他节点之间的联系更多，因此具有作为疾病的靶向分子的潜力 [<xref ref-type="bibr" rid="hanspub.34115-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.34115-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.34115-ref18">18</xref>]。表1和表2分别给出了胃癌和房颤PPI网络中排序前10的蛋白质的网络特征，这里称它们为疾病相关的重要靶向分子。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The network characteristics of top 10 key target molecules in PPI network of gastric cance</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >蛋白质</th><th align="center" valign="middle" >度</th><th align="center" valign="middle" >中介中心性</th><th align="center" valign="middle" >紧密中心性</th></tr></thead><tr><td align="center" valign="middle" >STAT3</td><td align="center" valign="middle" >108</td><td align="center" valign="middle" >0.07985666</td><td align="center" valign="middle" >0.29587267</td></tr><tr><td align="center" valign="middle" >FN1</td><td align="center" valign="middle" >106</td><td align="center" valign="middle" >0.05684914</td><td align="center" valign="middle" >0.28450275</td></tr><tr><td align="center" valign="middle" >EP300</td><td align="center" valign="middle" >95</td><td align="center" valign="middle" >0.05420104</td><td align="center" valign="middle" >0.27746188</td></tr><tr><td align="center" valign="middle" >RHOA</td><td align="center" valign="middle" >91</td><td align="center" valign="middle" >0.06726981</td><td align="center" valign="middle" >0.28080042</td></tr><tr><td align="center" valign="middle" >MAPK1</td><td align="center" valign="middle" >90</td><td align="center" valign="middle" >0.06396915</td><td align="center" valign="middle" >0.28590452</td></tr><tr><td align="center" valign="middle" >CTNNB1</td><td align="center" valign="middle" >82</td><td align="center" valign="middle" >0.05496279</td><td align="center" valign="middle" >0.27472809</td></tr><tr><td align="center" valign="middle" >ITGB1</td><td align="center" valign="middle" >78</td><td align="center" valign="middle" >0.03194662</td><td align="center" valign="middle" >0.26782262</td></tr><tr><td align="center" valign="middle" >CDC42</td><td align="center" valign="middle" >71</td><td align="center" valign="middle" >0.02086724</td><td align="center" valign="middle" >0.25111111</td></tr><tr><td align="center" valign="middle" >TP53</td><td align="center" valign="middle" >67</td><td align="center" valign="middle" >0.04663792</td><td align="center" valign="middle" >0.26945281</td></tr><tr><td align="center" valign="middle" >SRC</td><td align="center" valign="middle" >64</td><td align="center" valign="middle" >0.03141927</td><td align="center" valign="middle" >0.28812991</td></tr></tbody></table></table-wrap><p>表1. 胃癌PPI网络中排序前10的重要靶向分子的网络特征</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The network characteristics of top 10 key target molecules in PPI network of atrial fibrillatio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >蛋白质</th><th align="center" valign="middle" >度</th><th align="center" valign="middle" >中介中心性</th><th align="center" valign="middle" >紧密中心性</th></tr></thead><tr><td align="center" valign="middle" >CXCL8</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >0.09497645</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >CXCL1</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >0.09497645</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >CCL5</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >0.02904239</td><td align="center" valign="middle" >0.93333333</td></tr><tr><td align="center" valign="middle" >CXCL2</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >0.02904239</td><td align="center" valign="middle" >0.93333333</td></tr><tr><td align="center" valign="middle" >CXCR2</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >0.01255887</td><td align="center" valign="middle" >0.875</td></tr><tr><td align="center" valign="middle" >CXCR1</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >0.01255887</td><td align="center" valign="middle" >0.875</td></tr><tr><td align="center" valign="middle" >CXCL6</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >0.01255887</td><td align="center" valign="middle" >0.875</td></tr><tr><td align="center" valign="middle" >ACTA1</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >0.82222222</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >MSLN</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >0.64444444</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >DEFA3</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >0.43636364</td><td align="center" valign="middle" >0.91666667</td></tr></tbody></table></table-wrap><p>表2. 房颤PPI网络中排序前10的重要靶向分子的网络特征</p></sec></sec><sec id="s6"><title>4. 讨论</title><sec id="s6_1"><title>4.1. 胃癌和房颤的分子生物特征比较</title><p>比较胃癌和房颤相关的差异表达mRNAs所富集的GO条目，我们发现胃癌和房颤在生物功能和通路等分子生物特征方面既存在差异的特征，也包含相同的特征。这些差异体现在胃癌的差异表达mRNAs富集到细胞粘附(cell adhesion)、血管新生(angiogenesis)、基膜(basement membrane)和肝素结合(heparin binding)等生物功能和化学致癌性(chemical carcinogenesis)以及癌症通路(pathways in cancer)等通路。然而，房颤的差异表达mRNAs富集到骨骼肌纤维发育(skeletal muscle fiber development)、高尔基腔(golgi lumen)和凹痕结合(notch binding)等生物功能。</p><p>细胞粘附在细胞外基质上是腹膜癌发生的基础，而磷脂(Phospholipids)可以减少胃癌细胞对细胞外基质的粘附 [<xref ref-type="bibr" rid="hanspub.34115-ref19">19</xref>]。由于肿瘤血管生成依赖于内皮细胞的生存能力，因此，靶向survivin有利于新生血管的凋亡退化，从而间接抑制肿瘤的形成。胃癌上皮细胞中survivin的抑制导致了肿瘤生长相关血管生成的减少 [<xref ref-type="bibr" rid="hanspub.34115-ref20">20</xref>]。Takeda等学者对早期胃癌原发灶和转移灶的基底膜成分进行组织学和免疫组织化学检测，发现转移病灶基底膜区和基质组织的网状纤维比原发病灶丰富得多，而且与未分化腺癌相比，分化腺癌的层粘连蛋白、IV型胶原蛋白和纤连蛋白在基底膜的分布更为强烈 [<xref ref-type="bibr" rid="hanspub.34115-ref21">21</xref>]。表皮生长因子和表皮生长因子受体家族的激活与多种肿瘤类型的进展相关，Chung等学者发现血清sHB-EGF (soluble heparin-binding epidermal growth factor, sHB-EGF)与晚期胃癌密切相关，并认为是一种有前途的胃癌血清学生物标志物 [<xref ref-type="bibr" rid="hanspub.34115-ref22">22</xref>]。心房颤动时右心房心肌与血清的地高辛浓度比值和右心房心肌与骨骼肌浓度的地高辛浓度比值差异明显大于窦性心律。这可能部分地解释为房颤时肌细胞心房激活频率发生了变化 [<xref ref-type="bibr" rid="hanspub.34115-ref23">23</xref>]。</p><p>另外，我们发现它们有4条相同的生物进程和2条相同的细胞组分，如图4所示。在分子功能的条目中没有发现相同项。由于房颤的差异表达mRNAs没有富集到显著的生物通路，因此两种疾病之间没有发现相同的显著的生物通路。</p><p>图4. 胃癌和房颤相同的GO条目。(a)：生物进程，(b)：细胞组分。柱状图旁边的数字代表富集到该条目的差异表达mRNAs的数量</p><p>胃癌和房颤在生物进程方面有4个相同项(图4(a))，分别是趋化性、免疫反应、上皮细胞分化和中性粒细胞趋化的正调控；在细胞组分方面有2个相同项(图4(b))，分别是细胞外隙和细胞外的外泌体。趋化是一种细胞运动受细胞外化学梯度影响的现象。肿瘤细胞在周围微环境中的趋化是肿瘤进展和转移过程中扩散的重要组成部分。趋化性被认为参与了肿瘤细胞传播的每一个关键步骤。癌细胞及肿瘤相关炎症细胞和基质细胞的趋化性是由趋化因子、趋化因子受体、生长因子受体和生长因子受体介导的 [<xref ref-type="bibr" rid="hanspub.34115-ref24">24</xref>]。房颤后心脏成纤维细胞对血清有趋化作用 [<xref ref-type="bibr" rid="hanspub.34115-ref25">25</xref>]。</p><p>免疫系统在控制肿瘤的生长和进展中起着重要作用，适当的免疫反应可以通过癌症免疫监测系统抑制或消除肿瘤 [<xref ref-type="bibr" rid="hanspub.34115-ref26">26</xref>]。免疫反应参与房颤的发病机制。例如，Liu等人 [<xref ref-type="bibr" rid="hanspub.34115-ref27">27</xref>] 的研究表明，CD<sup>4+</sup> T细胞或髓样树突状细胞(myeloid dendritic cells)的PD-1/PD-L1 (Programmed death-1 (PD-1)/PD-1 ligand (PD-L))下调可能调节免疫调控并在房颤致病中发挥作用。</p><p>中性粒细胞是最丰富的循环粒细胞群，在感染或组织损伤后立即或早期被招募到发炎组织，而炎症是与包括胃癌在内的许多肿瘤的发生、发展和转移密切相关的 [<xref ref-type="bibr" rid="hanspub.34115-ref26">26</xref>]。外泌体包含许多物质，包括生长因子、趋化因子、ECM蛋白(extracellular matrix, ECM)、受体和蛋白酶，这些物质可以影响细胞运动的各个方面。在癌症中，外泌体已被证明影响许多肿瘤特性，包括生长、血管生成、侵袭和转移。外泌体的分泌促进癌细胞的趋化 [<xref ref-type="bibr" rid="hanspub.34115-ref28">28</xref>]。</p><p>由此可见，趋化性和免疫反应不仅与胃癌有关，而且与房颤的发生发展也有关系。中性粒细胞和外泌体与胃癌的发生发展有关系，而它们与房颤的关系也值得进一步的研究。</p></sec><sec id="s6_2"><title>4.2. 胃癌和房颤相关的重要靶向分子比较</title><p>胃癌相关的重要靶向分子中，已有文献报道STAT3、FN1、EP300、RHOA、MAPK1、CTNNB1、ITGB1、CDC42和TP53与胃癌的发生发展有关。例如，炎症条件可以启动或促进致癌转化，而且恶性细胞在遗传和表观遗传的变化也可以产生炎性微环境，而进一步促进肿瘤的发展。STAT家族蛋白是决定肿瘤微环境中的免疫反应是促进还是抑制癌症的关键。STAT3的持续激活可以介导促肿瘤炎症 [<xref ref-type="bibr" rid="hanspub.34115-ref29">29</xref>]。在肿瘤发生过程中，STAT3参与细胞存活和增殖。抑制STAT3可显著降低survivin的表达，而survivin的强制表达可使胃癌细胞免于STAT3的诱导凋亡。由此可见，STAT3可能是胃癌细胞中survivin表达的调控因子，并通过调控survivin的表达参与肿瘤的进展 [<xref ref-type="bibr" rid="hanspub.34115-ref30">30</xref>]。在胃癌组织中，STAT3的表达还与淋巴结转移有显著的相关性 [<xref ref-type="bibr" rid="hanspub.34115-ref31">31</xref>]。有研究指出其它分子也可以通过调控STAT3来影响胃癌的迁移。CXCR4的过表达促进胃癌生长和转移，它通过激活STAT3促进胃癌肿瘤血管生成 [<xref ref-type="bibr" rid="hanspub.34115-ref32">32</xref>]。miR-125a通过靶向STAT3抑制胃癌细胞的迁移和侵袭 [<xref ref-type="bibr" rid="hanspub.34115-ref33">33</xref>]。Kim等的研究说明STAT3与胃癌的TNM分期和生存率有显著的相关性，因此STAT3可作为预测胃癌不良预后的分子分期标志物 [<xref ref-type="bibr" rid="hanspub.34115-ref34">34</xref>]。根据胃癌中FN1的低、中、高表达的中位生存时间的分析，发现低表达和高表达者中位生存时间差异具有统计学意义，而且FN1高表达者中位生存时间短于低表达者，所以推测FN1表达越高，预后越差 [<xref ref-type="bibr" rid="hanspub.34115-ref35">35</xref>]。miR-200c可特异性与FN1的3’-UTR结合，显著抑制荧光素酶活性，而且过表达miR-200c后，胃癌细胞中FN1的mRNA和蛋白质表达均明显下降。研究者同时观察到过表达miR-200c或下调FN1均可抑制胃癌细胞的增殖、迁移和侵袭。由此可见，miR-200c通过与FN1结合可以抑制胃癌细胞的增殖、迁移和侵袭 [<xref ref-type="bibr" rid="hanspub.34115-ref36">36</xref>] [<xref ref-type="bibr" rid="hanspub.34115-ref37">37</xref>]。EP300的移码突变及其表达丢失可能是胃癌微卫星高度不稳定性的一个特征 [<xref ref-type="bibr" rid="hanspub.34115-ref38">38</xref>]。在胃癌细胞中，RHOA定位于细胞膜、胞质和细胞核内 [<xref ref-type="bibr" rid="hanspub.34115-ref39">39</xref>]。RHOA的mRNA和蛋白质表达水平在胃癌组织中都升高，并与TNM分期相关 [<xref ref-type="bibr" rid="hanspub.34115-ref40">40</xref>]。MAPK是广泛存在于细胞中的蛋白激酶家族，在多种疾病的免疫应答中发挥重要作用。物理或化学的刺激可以激活MAPK1蛋白，进而激活P38信号通路，启动级联反应，进而调节机体免疫反应 [<xref ref-type="bibr" rid="hanspub.34115-ref41">41</xref>]。miR-585 [<xref ref-type="bibr" rid="hanspub.34115-ref41">41</xref>] 、miR-378 [<xref ref-type="bibr" rid="hanspub.34115-ref42">42</xref>] 和miR-217 [<xref ref-type="bibr" rid="hanspub.34115-ref43">43</xref>] 通过靶向MAPK1抑制胃癌细胞增殖、细胞周期进展、细胞迁移和侵袭。FOXP3通过激活胃癌细胞凋亡信号通路，抑制细胞增殖，诱导胃癌细胞凋亡。FOXP3表达水平与CTNNB1表达呈正相关，它正向调控CTNNB1并直接与之结合。因此，Pan等研究者推测FOXP3抑制胃癌细胞侵袭转移可能是通过调控CTNNB1来实现 [<xref ref-type="bibr" rid="hanspub.34115-ref44">44</xref>]。hTERT在肿瘤的侵袭和转移中起重要作用。He等研究者发现上调hTERT可以抑制miR-29a的表达和提高ITGB1的表达，而且miR-29a的表达水平的恢复抑制了ITGB1的表达，并抑制了胃癌细胞的转移。因此，他们认为hTERT可能通过miR-29a间接靶向ITGB1介导胃癌转移 [<xref ref-type="bibr" rid="hanspub.34115-ref45">45</xref>]。Hu等研究者也发现hTERT增加了胃癌中ITGB1的表达，hTERT水平与人胃癌组织中ITGB1水平呈正相关，而且hTERT-FOXO3a-ITGB1通路对hTERT促进胃癌侵袭有显著作用，因此他们认为hTERT通过增强FOXO3a和ITGB1上调来促进胃癌细胞的侵袭 [<xref ref-type="bibr" rid="hanspub.34115-ref46">46</xref>]。CDC42是小GTPases的Rho家族的成员，它被认为是细胞分化的分子开关。CDC42基因的敲出明显抑制胃癌细胞的增殖、迁移和侵袭，这个抑制过程可能是由于细胞周期被阻滞在G1/S期，并下调了细胞周期蛋白A、细胞周期蛋白D1、细胞周期蛋白E的表达以及抑制基质金属蛋白酶9的表达 [<xref ref-type="bibr" rid="hanspub.34115-ref47">47</xref>]。miR-133在胃癌中是CDC42负调控的关键因子，它在胃癌组织中显著下调，其表达值与肿瘤大小、浸润深度和周围器官转移呈负相关 [<xref ref-type="bibr" rid="hanspub.34115-ref48">48</xref>]。miR-148b-3p通过抑制CDC42来抑制胃癌转移 [<xref ref-type="bibr" rid="hanspub.34115-ref49">49</xref>]。由此可见，CDC42影响胃癌的发生发展。TP53基因在胃癌中经常发生突变，具有TP53突变的胃癌似乎发展为分化的组织学类型，并表现出如静脉侵犯等具有侵略性的生物学行为，所以Tahara等研究者认为区分TP53热点突变(R175、G245、R248、R273、R282)对预测胃癌患者较差的总生存期和无复发生存期具有一定的重要性 [<xref ref-type="bibr" rid="hanspub.34115-ref50">50</xref>]。由上述可知，我们从胃癌的PPI网络中有效的筛选到了一些潜在的靶向分子，这些靶向分子与胃癌的发生发展产生一定的影响。尤其是FN1、EP300、CTNNB1和TP53这几个潜在的靶向分子，它们的mRNA根据本文的分析，在胃癌中都具有显著性的差异表达，其中FN1和TP53显著上调，而EP300和CTNNB1显著下调。因此，它们在胃癌中的作用值得深入的探索。</p><p>房颤相关的重要靶向分子中，已有文献报道CXCL8和CCL5可能与房颤的发生发展有关。Abdalla等研究者通过对由寨卡病毒(Zika virus)感染的房颤患者的研究发现与未感染的对照组相比，房颤患者可观察到CXCL8水平升高，而且与其他寨卡患者相比，只在房颤患者中发现CCL5水平升高 [<xref ref-type="bibr" rid="hanspub.34115-ref51">51</xref>]。在本研究的房颤–对照mRNA表达数据中，重要靶向分子CXCL1、CXCR2、ACTA1、MSLN和DEFA3的mRNA表达水平显著性差异表达。其中CXCR2和DEFA3显著上调，而CXCL1、ACTA1和MSLN显著下调。它们在房颤中的作用目前还没有相关的文献报道，因此还需要进一步的实验验证。</p><p>两种疾病没有相同的重要靶向分子。然而，我们发现房颤相关的重要靶向分子CXCL1和CXCR2的mRNA表达水平在两种疾病中都显著地差异表达。CXCL1在胃癌中上调，但在房颤中下调；CXCR2在两种疾病中都处于上调。CXCL1和CXCR2都与趋化性、免疫反应有关，根据4.1节的分析可知，趋化性和免疫反应在胃癌和房颤的发生发展中起着一定的作用。已有文献报道CXCL1和CXCR2与胃癌的发生发展有关。例如，淋巴管内皮细胞分泌的CXCL1刺激胃癌的淋巴管生成和转移 [<xref ref-type="bibr" rid="hanspub.34115-ref52">52</xref>]。肿瘤相关淋巴管内皮细胞的CXCL1通过激活整合素β1/FAK/AKT信号通路将胃癌细胞送入淋巴系统 [<xref ref-type="bibr" rid="hanspub.34115-ref53">53</xref>]。CXCL1增强了肿瘤的生长，并与胃癌较差的生存率相关。它通过活化STAT3来增强血管内皮生长因子(VEGF)的表达，从而促进胃癌血管生成和肿瘤生长 [<xref ref-type="bibr" rid="hanspub.34115-ref54">54</xref>]。CXCR2主要表达于胃癌细胞的细胞质中。CXCR2高表达与肿瘤分化差、肿瘤深度增加、淋巴结转移、TNM分期进展及总生存期短有关 [<xref ref-type="bibr" rid="hanspub.34115-ref55">55</xref>]。化学激酶介导的G蛋白偶联受体CXCR1和CXCR2的活化促进肿瘤生长、侵袭、炎症和转移 [<xref ref-type="bibr" rid="hanspub.34115-ref56">56</xref>]。CXCR1和CXCR2蛋白的过表达促进了胃肿瘤细胞的迁移和侵袭 [<xref ref-type="bibr" rid="hanspub.34115-ref57">57</xref>]。Xiang等人 [<xref ref-type="bibr" rid="hanspub.34115-ref58">58</xref>] 的研究指出，CXCR4和CXCR2在高侵袭性胃癌细胞模型和胃癌组织中均高表达，而且它们的过表达与胃癌晚期和生存期较差有关；更重要的是，CXCR1和CXCR2的表达具有很强的相关性，且都可以激活NF-κB和STAT3信号，而NF-κBp65可以转录激活CXCR4，同时STAT3可以激活CXCR2的表达；CXCR4和CXCR2之间的这种相互作用促进了上皮-间充质转变(epithelial-mesenchymal transition, EMT)、胃癌的迁移和侵袭。另外，CXCR4在患有二尖瓣疾病的慢性房颤患者中表达上调，而且它与心房重构相关 [<xref ref-type="bibr" rid="hanspub.34115-ref59">59</xref>]。尽管CXCR4没有被列为两种疾病相关的重要靶向分子，目前也还没有文献报道CXCR2与房颤的关系，但是现有生物证据表明，CXCR4和CXCR2均与胃癌的发生发展相关，CXCR4与心房重构相关，且二者的表达高度相关。</p></sec></sec><sec id="s7"><title>5. 结论</title><p>我们基于胃癌和房颤的mRNA表达谱，比较和分析了两种疾病相关的差异表达mRNAs富集的生物功能和通路，发现两种疾病具有一些相同的分子生物特征。两种疾病的差异表达mRNAs都富集到趋化性(chemotaxis)、免疫反应(immune response)、上皮细胞分化(epithelial cell differentiation)、中性粒细胞趋化的正调控(positive regulation of neutrophil chemotaxis)、细胞外隙(extracellular space)和细胞外的外泌体(extracellular exosome)。目前，已有相应的文献报道趋化性和免疫反应与胃癌和房颤的发生发展有关系。尽管我们没有发现两种疾病有相同的重要靶向分子，但是房颤相关的重要靶向分子CXCR2的mRNA表达水平在两种疾病中都显著地差异表达。CXCR2与胃癌的发生发展有关，推测它可能通过与CXCR4的相互作用影响房颤。这些研究为进一步理解癌症合并房颤或房颤合并癌症的机制提供了一定的理论基础。</p><p>在未来的研究中，我们将收集胃癌合并房颤或房颤合并胃癌样本，构建mRNA表达谱，研究癌症与房颤共病的分子机制，为研发治疗二者共病时的新药提供新视线。</p></sec><sec id="s8"><title>致谢</title><p>本文得到了国家自然科学基金(61872405和31771079)和广东省自然科学基金重点项目(2016A030311 040)支持，在此表示感谢。</p></sec><sec id="s9"><title>文章引用</title><p>曾 伟,董昌龙,高枫林,王光斌,曾红娟,饶妮妮. 基于mRNA表达谱比较胃癌和房颤的分子生物特征Comparing the Molecular Biological Characteristics between Gastric Cancer and Atrial Fibrillation Based on mRNA Expression Profiles[J]. 计算生物学, 2020, 10(01): 1-14. https://doi.org/10.12677/HJCB.2020.101001</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.34115-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Khan, N., Afaq, F. and Mukhtar, H. (2010) Lifestyle as Risk Factor for Cancer: Evidence from Human Studies. Cancer Letters, 293, 133-143. https://doi.org/10.1016/j.canlet.2009.12.013</mixed-citation></ref><ref id="hanspub.34115-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Ling, L.-H., Kistler, P.M., Kalman, J.M., Schilling, R.J. and Hunter, R.J. (2016) Comorbidity of Atrial Fibrillation and Heart Failure. Nature Reviews Cardiology, 13, 131-147. https://doi.org/10.1038/nrcardio.2015.191</mixed-citation></ref><ref id="hanspub.34115-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Wutzler, A., Krogias, C., Grau, A., Veltkamp, R., Heuschmann, P.U. and Haeusler, K.G. (2019) Stroke Prevention in Patients with Acute Ischemic Stroke and Atrial Fibrillation in Germany—A Cross Sectional Survey. BMC Neurology, 19, 1-4. https://doi.org/10.1186/s12883-019-1249-y</mixed-citation></ref><ref id="hanspub.34115-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Anumonwo, J.M.B. and Kalifa, J. (2016) Risk Factors and Genetics of Atrial Fibrillation. Cardiology Clinics, 12, 157-166. https://doi.org/10.1016/j.hfc.2015.08.013</mixed-citation></ref><ref id="hanspub.34115-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Tu, N.N., Hilmer, S.N. and Cumming, R.G. (2013) Review of Epidemiology and Management of Atrial Fibrillation in Developing Countries. International Journal of Cardiology, 167, 2412-2420. https://doi.org/10.1016/j.ijcard.2013.01.184</mixed-citation></ref><ref id="hanspub.34115-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Fumagalli, S., Barchielli, A., Tarantini, F., Gabbai, D., Rinaldi, M.C., Fracchia, S., et al. (2012) Atrial Fibrillation and Cancer: Evidence for an Epidemiological Link. Journal of the American College of Cardiology, 59, E615.https://doi.org/10.1016/S0735-1097(12)60616-0</mixed-citation></ref><ref id="hanspub.34115-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Hung, C.S., Chang, C.H., Lin, J.W., Ho, Y.L. and Chen, M.F. (2018) The Association between New Onset Atrial Fibrillation and Incident Cancer—A Nationwide Cohort Study. PLoS ONE, 13, e0199901. https://doi.org/10.1371/journal.pone.0199901</mixed-citation></ref><ref id="hanspub.34115-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Jacob, K.A., Nathoe, H.M., Dieleman, J.M., van Osch, D., Kluin, J. and van Dijk, D. (2014) Inflammation in New-Onset Atrial Fibrillation after Cardiac Surgery: A Systematic Review. European Journal of Clinical Investigation, 44, 402-428. https://doi.org/10.1111/eci.12237</mixed-citation></ref><ref id="hanspub.34115-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Rahman, F., Ko, D. and Benjamin, E.J. (2016) Association of Atrial Fibrillation and Cancer. JAMA Cardiology, 1, 384-386. https://doi.org/10.1001/jamacardio.2016.0582</mixed-citation></ref><ref id="hanspub.34115-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Fitzpatrick, T., Carrier, M. and Gal, G.L. (2017) Cancer, Atrial Fibrillation, and Stroke. Thrombosis Research, 155, 101-105. https://doi.org/10.1016/j.thromres.2017.05.006</mixed-citation></ref><ref id="hanspub.34115-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">O’Neal, W.T., Lakoski, S.G., et al. (2015) Relation between Cancer and Atrial Fibrillation (From the Reasons for Geographic and Racial Differences in Stroke Study). The American Journal of Cardiology, 115, 1090-1094.https://doi.org/10.1016/j.amjcard.2015.01.540</mixed-citation></ref><ref id="hanspub.34115-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Dimitrios, F., John, P. and Gerasimos, F. (2014) Insights into Onco-Cardiology: Atrial Fibrillation in Cancer. Journal of the American College of Cardiology, 63, 945-953. https://doi.org/10.1016/j.jacc.2013.11.026</mixed-citation></ref><ref id="hanspub.34115-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Cheng, W.L., Kao, Y.H., Chen, S.A. and Chen, Y.J. (2016) Pathophysiology of Cancer Therapy-Provoked Atrial Fibrillation. International Journal of Cardiology, 219, 186-194. https://doi.org/10.1016/j.ijcard.2016.06.009</mixed-citation></ref><ref id="hanspub.34115-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Lee, Y.Y. and Derakhshan, M.H. (2013) Environmental and Lifestyle Risk Factors of Gastric Cancer. Archives of Iranian Medicine, 16, 358-365.</mixed-citation></ref><ref id="hanspub.34115-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Andrea, F., Damian, S., Sune, F., Michael, K., Milan, S., Alexander, R., et al. (2013) STRING v9.1: Protein-Protein Interaction Networks, with Increased Coverage and Integration. Nucleic Acids Research, 41, D808-D815.https://doi.org/10.1093/nar/gks1094</mixed-citation></ref><ref id="hanspub.34115-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Poos, K., Smida, J., Nathrath, M., Maugg, D., Baumhoer, D. and Korsching, E. (2012) How MicroRNA and Transcription Factor Co-Regulatory Networks Affect Osteosarcoma Cell Proliferation. PLoS Computational Biology, 9, 262-279.https://doi.org/10.1371/journal.pcbi.1003210</mixed-citation></ref><ref id="hanspub.34115-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Feng, Y., Wang, Q. and Wang, T. (2017) Drug Target Protein-Protein Interaction Networks: A Systematic Perspective. Biomed Research International, 2017, Article ID: 1289259. https://doi.org/10.1155/2017/1289259</mixed-citation></ref><ref id="hanspub.34115-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Chea, E. and Livesay, D.R. (2007) How Accurate and Statistically Robust Are Catalytic Site Predictions Based on Closeness Centrality? BMC Bioinformatics, 8, 153-166. https://doi.org/10.1186/1471-2105-8-153</mixed-citation></ref><ref id="hanspub.34115-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Jansen, M., Treutner, K.H., Schmitz, B., Otto, J. and Schumpelick, V. (2004) Phospholipids Reduce Gastric Cancer Cell Adhesion to Extracellular Matrix in Vitro. BMC Gastroenterology, 4, 33-37. https://doi.org/10.1186/1471-230X-4-33</mixed-citation></ref><ref id="hanspub.34115-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Tu, S., Jiang, X., Lin, M., Cui, J., Yang, Y., Lum, C., et al. (2003) Suppression of Survivin Expression Inhibits in Vivo Tumorigenicity and Angiogenesis in Gastric Cancer. Cancer Research, 63, 7724-7732.</mixed-citation></ref><ref id="hanspub.34115-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Takeda, H. (1990) Immunohistochemical Studies of Basement Membrane Components in Primary and Metastatic Lesions of Early Gastric Cancer. Journal of Nippon Medical School, 57, 160-171. https://doi.org/10.1272/jnms1923.57.160</mixed-citation></ref><ref id="hanspub.34115-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Chung, H., Kong, H. and Lim, J.-B. (2015) Clinical Significance and Usefulness of Soluble Heparin Binding-Epidermal Growth Factor in Gastric Cancer. World Journal of Gastroenterology, 21, 2080-2088. https://doi.org/10.3748/wjg.v21.i7.2080</mixed-citation></ref><ref id="hanspub.34115-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Jogestrand, T. (1980) Digoxin Concentration in Right Atrial Myocardium, Skeletal Muscle and Serum in Man: Influence of Atrial Rhythm. European Journal of Clinical Pharmacology, 17, 243-250.https://doi.org/10.1007/BF00625797</mixed-citation></ref><ref id="hanspub.34115-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Roussos, E.T., Condeelis, J.S. and Antonia, P. (2011) Chemotaxis in Cancer. Nature Reviews Cancer, 11, 573-587.https://doi.org/10.1038/nrc3078</mixed-citation></ref><ref id="hanspub.34115-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Duan, K.D., Li, Y.-S. and Shi, X.J. (2011) Effects of Serum from Patients with Atrial Fibrillation on Chemotaxis of Cardiac Fibroblasts. Chinese Journal of Pathophysiology, 27, 662-665.</mixed-citation></ref><ref id="hanspub.34115-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Lee, K., Hwang, H. and Nam, K.T. (2014) Immune Response and the Tumor Microenvironment: How They Communicate to Regulate Gastric Cancer. Gut &amp; Liver, 8, 131-139. https://doi.org/10.5009/gnl.2014.8.2.131</mixed-citation></ref><ref id="hanspub.34115-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Liu, L., Zheng, Q., Lee, J., Ma, Z., Zhu, Q. and Wang, Z. (2015) PD-1/PD-L1 Expression on CD4+ T Cells and Myeloid DCs Correlates with the Immune Pathogenesis of Atrial Fibrillation. Journal of Cellular &amp; Molecular Medicine, 19, 1223-1233. https://doi.org/10.1111/jcmm.12467</mixed-citation></ref><ref id="hanspub.34115-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Sung, B.H. and Weaver, A.M. (2017) Exosome Secretion Promotes Chemotaxis of Cancer Cells. Cell Adhesion &amp; Migration, 11, 187-195. https://doi.org/10.1080/19336918.2016.1273307</mixed-citation></ref><ref id="hanspub.34115-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Hua, Y., Drew, P. and Richard, J. (2009) STATs in Cancer Inflammation and Immunity: A Leading Role for STAT3. Nature Reviews Cancer, 11, 798-809. https://doi.org/10.1038/nrc2734</mixed-citation></ref><ref id="hanspub.34115-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Kanda, N., Seno, H., Konda, Y., Marusawa, H. and Chiba, T. (2004) STAT3 Is Constitutively Activated and Supports Cell Survival in Association with Survivin Expression in Gastric Cancer Cells. Oncogene, 23, 4921-4929.https://doi.org/10.1038/sj.onc.1207606</mixed-citation></ref><ref id="hanspub.34115-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Deng, J., Liang, H., Zhang, R., Sun, D., Pan, Y., Liu, Y., et al. (2013) STAT3 Is Associated with Lymph Node Metastasis in Gastric Cancer. Tumor Biology, 34, 2791-2800. https://doi.org/10.1007/s13277-013-0837-5</mixed-citation></ref><ref id="hanspub.34115-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Q., Xu, F., Shi, Y., Chen, Y.W., Wang, H.P., Yu, X., et al. (2017) C-X-C Motif Chemokine Receptor 4 Promotes Tumor Angiogenesis in Gastric Cancer via Activation of JAK2/STAT3. Cell Biology International, 41, 854-862.https://doi.org/10.1002/cbin.10794</mixed-citation></ref><ref id="hanspub.34115-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Yang, L., Zhang, S., Guo, K., Huang, H., Qi, S., Yao, J., et al. (2018) miR-125a Restrains Cell Migration and Invasion by Targeting STAT3 in Gastric Cancer Cells. OncoTargets and Therapy, 12, 205-215.https://doi.org/10.2147/OTT.S168454</mixed-citation></ref><ref id="hanspub.34115-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Kim, D.Y., Cha, S.T., Ahn, D.H., Kang, H.Y., Kwon, C.I., Ko, K.H., et al. (2009) STAT3 Expression in Gastric Cancer Indicates a Poor Prognosis. Journal of Gastroenterology &amp; Hepatology, 24, 646-651.https://doi.org/10.1111/j.1440-1746.2008.05671.x</mixed-citation></ref><ref id="hanspub.34115-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">孙阳, 赵春临. 纤维连接蛋白1在胃癌中的表达及临床意义[J]. 医学研究生学报, 2019, 32(6): 629-633.</mixed-citation></ref><ref id="hanspub.34115-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, H., Sun, Z., Li, Y., Fan, D. and Jiang, H. (2017) MicroRNA-200c Binding to FN1 Suppresses the Proliferation, Migration and Invasion of Gastric Cancer Cells. Biomedicine &amp; Pharmacotherapy, 88, 285-292.https://doi.org/10.1016/j.biopha.2017.01.023</mixed-citation></ref><ref id="hanspub.34115-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Chen, H.B. and Zheng, H.T. (2017) MicroRNA-200c Represses Migration and Invasion of Gastric Cancer SGC-7901 Cells by Inhibiting Expression of Fibronectin 1. European Review for Medical and Pharmacological Sciences, 21, 1753-1758.</mixed-citation></ref><ref id="hanspub.34115-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Kim, M.S., Lee, S.H., Yoo, N.J. and Lee, S.H. (2013) Frameshift Mutations of Tumor Suppressor Gene EP300 in Gastric and Colorectal Cancers with High Microsatellite Instability. Human Pathology, 44, 2064-2070.https://doi.org/10.1016/j.humpath.2012.11.027</mixed-citation></ref><ref id="hanspub.34115-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Tao, Y., Chen, Y.C., Li, Y.Y., Yang, S.Q. and Xu, W.R. (2008) Localization and Translocation of RhoA Protein in the Human Gastric Cancer Cell Line SGC-7901. World Journal of Gastroenterology, 14, 1175-1181.https://doi.org/10.3748/wjg.14.1175</mixed-citation></ref><ref id="hanspub.34115-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Yoon, J.H., Choi, W.S., Kim, O., Choi, B.J. and Park, W.S. (2016) Gastrokine 1 Inhibits Gastric Cancer Cell Migration and Invasion by Downregulating RhoA Expression. Gastric Cancer, 20, 1-12. https://doi.org/10.1007/s10120-016-0617-1</mixed-citation></ref><ref id="hanspub.34115-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Hu, L., Wu, H., Wan, X., Liu, L., He, Y., Zhu, L., et al. (2018) MicroRNA-585 Suppresses Tumor Proliferation and Migration in Gastric Cancer by Directly Targeting MAPK1. Biochemical and Biophysical Research Communications, 499, 52-58. https://doi.org/10.1016/j.bbrc.2018.03.116</mixed-citation></ref><ref id="hanspub.34115-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Bojian, F. and Haorong, W. (2012) MiR-378 Inhibits Progression of Human Gastric Cancer MGC-803 Cells by Targeting MAPK1 in Vitro. Oncology Research, 20, 557-564. https://doi.org/10.3727/096504013X13775486749254</mixed-citation></ref><ref id="hanspub.34115-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">卢燕华, 唐三元. miR-217靶向MAPK1抑制胃癌细胞侵袭转移作用研究[J]. 中国现代医药杂志, 2014, 16(11): 21-23.</mixed-citation></ref><ref id="hanspub.34115-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Pan, D.Y., Zeng, X.Q., Ma, G.F., Gao, J., Li, N., Miao, Q., et al. (2018) Label-Free Quantitative Proteomic Analysis Identifies CTNNB1 as a Direct Target of FOXP3 in Gastric Cancer Cells. Oncology Letters, 15, 7655-7660.https://doi.org/10.3892/ol.2018.8277</mixed-citation></ref><ref id="hanspub.34115-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">He, B., Xiao, Y.-F., Tang, B., Wu, Y.-Y., Hu, C.-J., Xie, R., et al. (2016) hTERT Mediates Gastric Cancer Metastasis Partially through the Indirect Targeting of ITGB1 by microRNA-29a. Scientific Reports, 6, 1-12.https://doi.org/10.1038/srep21955</mixed-citation></ref><ref id="hanspub.34115-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Hu, C., Ni, Z., Li, B.S., Yong, X. and Yang, S.-M. (2015) hTERT Promotes the Invasion of Gastric Cancer Cells by Enhancing FOXO3a Ubiquitination and Subsequent ITGB1 Upregulation. Gut, 66, 31-42.https://doi.org/10.1136/gutjnl-2015-309322</mixed-citation></ref><ref id="hanspub.34115-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Du, D., Yang, X., Wang, Q., Dai, W., Kuai, W., Liu, Y.L., et al. (2016) Effects of CDC42 on the Proliferation and Invasion of Gastric Cancer Cells. Molecular Medicine Reports, 13, 550-554. https://doi.org/10.3892/mmr.2015.4523</mixed-citation></ref><ref id="hanspub.34115-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Cheng, Z., Liu, F., Wang, G., Li, Y., Zhang, H. and Li, F. (2014) miR-133 Is a Key Negative Regulator of CDC42-PAK Pathway in Gastric Cancer. Cellular Signalling, 26, 2667-2673. https://doi.org/10.1016/j.cellsig.2014.08.012</mixed-citation></ref><ref id="hanspub.34115-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Li, X., Jiang, M., Chen, D., Xu, B., Wang, R., Chu, Y., et al. (2018) miR-148b-3p Inhibits Gastric Cancer Metastasis by Inhibiting the Dock6/Rac1/Cdc42 Axis. Journal of Experimental &amp; Clinical Cancer Research, 37, 71-85.https://doi.org/10.1186/s13046-018-0729-z</mixed-citation></ref><ref id="hanspub.34115-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Tahara, T., Shibata, T., Okamoto, Y., Yamazaki, J. and Ohmiya, N. (2016) Mutation Spectrum of TP53 Gene Predicts Clinicopathological Features and Survival of Gastric Cancer. Oncotarget, 7, 42252-42260.https://doi.org/10.18632/oncotarget.9770</mixed-citation></ref><ref id="hanspub.34115-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Abdalla, L.F., Santos, J.H.A., Barreto, R.T.J., Souza, E.M., D’Assuncao, F.F., Borges, M.A., et al. (2018) Atrial Fibrillation in a Patient with Zika Virus Infection. Virology Journal, 15, 23-28. https://doi.org/10.1186/s12985-018-0938-2</mixed-citation></ref><ref id="hanspub.34115-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Xu, J.B., Zhang, C.H., He, Y.L., Hui, W., Zhao, W., Wu, S., et al. (2015) Lymphatic Endothelial Cell-Secreted CXCL1 Stimulates Lymphangiogenesis and Metastasis of Gastric Cancer. International Journal of Cancer, 130, 787-797. https://doi.org/10.1002/ijc.26035</mixed-citation></ref><ref id="hanspub.34115-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Z., Wang, Z., Li, G., Wu, H., Sun, K., Chen, J., et al. (2017) CXCL1 from Tumor-Associated Lymphatic Endothelial Cells Drives Gastric Cancer Cell into Lymphatic System via Activating Integrin β1/FAK/AKT Signaling. Cancer Letters, 385, 28-38. https://doi.org/10.1016/j.canlet.2016.10.043</mixed-citation></ref><ref id="hanspub.34115-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">Wei, Z.W., Xia, G.K., Wu, Y., Chen, W., Xiang, Z., Schwarz, R.E., et al. (2015) CXCL1 Promotes Tumor Growth through VEGF Pathway Activation and Is Associated with Inferior Survival in Gastric Cancer. Cancer Letters, 359, 335-343. https://doi.org/10.1016/j.canlet.2015.01.033</mixed-citation></ref><ref id="hanspub.34115-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Z., Liu, H., Shen, Z., Wang, X., Zhang, H., Qin, J., et al. (2015) The Prognostic Value of CXC-Chemokine Receptor 2 (CXCR2) in Gastric Cancer Patients. BMC Cancer, 15, 766-773. https://doi.org/10.1186/s12885-015-1793-9</mixed-citation></ref><ref id="hanspub.34115-ref56"><label>56</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J., Hu, W., Wang, K., Yu, J., Luo, B., Luo, G., et al. (2016) Repertaxin, an Inhibitor of the Chemokine Receptors CXCR1 and CXCR2, Inhibits Malignant Behavior of Human Gastric Cancer MKN45 Cells in Vitro and in Vivo and Enhances Efficacy of 5-Fluorouracil. International Journal of Oncology, 48, 1341-1352.https://doi.org/10.3892/ijo.2016.3371</mixed-citation></ref><ref id="hanspub.34115-ref57"><label>57</label><mixed-citation publication-type="other" xlink:type="simple">Li, Z., Wang, Y., Dong, S., Ge, C., Xiao, Y., Li, R., et al. (2014) Association of CXCR1 and 2 Expressions with Gastric Cancer Metastasis in Ex Vivo and Tumor Cell Invasion in Vitro. Cytokine, 69, 6-13.https://doi.org/10.1016/j.cyto.2014.05.004</mixed-citation></ref><ref id="hanspub.34115-ref58"><label>58</label><mixed-citation publication-type="other" xlink:type="simple">Xiang, Z., Zhou, Z.J., Xia, G.K., Zhang, X.H., Wei, Z.W., Zhu, J.T., et al. (2017) A Positive Crosstalk between CXCR4 and CXCR2 Promotes Gastric Cancer Metastasis. Oncogene, 36, 1-12. https://doi.org/10.1038/onc.2017.108</mixed-citation></ref><ref id="hanspub.34115-ref59"><label>59</label><mixed-citation publication-type="other" xlink:type="simple">Wang, X.X., Zhang, F.R., Zhu, J.H., Xie, X.D. and Chen, J.Z. (2009) Up-Regulation of CXC Chemokine Receptor 4 Expression in Chronic Atrial Fibrillation Patients with Mitral Valve Disease May Be Attenuated by Renin-Angiotensin System Blockers. Journal of International Medical Research, 37, 1145-1151. https://doi.org/10.1177/147323000903700419</mixed-citation></ref></ref-list></back></article>